(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 September 2021 (30.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/191464 A1

(51) International Patent Classification:
A61K 45/06 (2006.01) *A61P 35/00* (2006.01)
A61K 47/64 (2017.01)

(21) International Application Number:
PCT/EP2021/058146

(22) International Filing Date:
29 March 2021 (29.03.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2004514.2 27 March 2020 (27.03.2020) GB

(71) Applicants: **INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES** [PT/PT]; Av. Professor Egas Moniz, 1649-028 Lisbon (PT). **FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA** [PT/PT]; Av. Professor Egas Moniz, 1649-028 Lisbon (PT).

(72) Inventors: **LABÃO ALPIARÇA SOUSA DE ALMEIDA, Carlos Diogo**; c/o Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Av. Professor Egas Moniz, 1649-028 Lisboa (PT). **LOPES BERNARDES, Gonçalo José**; c/o Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Av. Professor Egas Moniz, 1649-028 Lisboa (PT).

(74) Agent: **GRUND, Martin**; GRUND Intellectual Property Group, Patentanwalt und Solicitor PartG mbB, Postfach 44 05 16, 80754 Munich (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2021/191464 A1

(54) Title: USE OF CONJUGATES COMPRISING TUMOUR-SELECTIVE LIGANDS AND GROUPS CAPABLE OF RELEASING CARBON MONOXIDE (CO), FOR EXERTING IMMUNOMODULATORY EFFECTS IN CANCER TREATMENT

(57) Abstract: The present invention in various aspects and embodiments involves the use of CO releasing molecules, such as conjugates comprising tumour-selective ligands and groups capable of releasing carbon monoxide (CO), for exerting immunomodulatory effects in cancer treatment, such as reductions in the expression of immune checkpoint molecules and the level of inhibitory macrophages. This can reduce immunosuppression in tumour tissue and can be useful, for example, in the treatment of immunosuppressive cancers or the treatment of cancers in combination with cancer immunotherapy.